A study by Mellqvist et al. has assessed the efficacy and safety of combined bolus-dose cyclophosphamide and pulse-dose dexamethasone (Cy-Dex) as initial treatment for patients with myeloma.

Cancer treatment is undergoing a revolution, and immunotherapy is leading the charge. Unlike traditional methods like ...

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Metastatic Pancreatic Cancer.

In patients who have received less than 14 days of dexamethasone therapy, treatment may be abruptly discontinued without adverse events, because the HPA axis is not suppressed (Kountz & Clark ...

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, an ...